DNMT1 and neoplasm: Subsequently, it was shown that the DNMT inhibitor 5-azacytidine combined with anti-PD-L1 therapy led to tumor regression accompanied by increased cytotoxic T-lymphocyte infiltration in mouse models compared to monotherapy (91).